KR20220148869A - 구조적으로 안정화된 항바이러스성 SARS-CoV-2 펩타이드 및 그의 용도 - Google Patents

구조적으로 안정화된 항바이러스성 SARS-CoV-2 펩타이드 및 그의 용도 Download PDF

Info

Publication number
KR20220148869A
KR20220148869A KR1020227033763A KR20227033763A KR20220148869A KR 20220148869 A KR20220148869 A KR 20220148869A KR 1020227033763 A KR1020227033763 A KR 1020227033763A KR 20227033763 A KR20227033763 A KR 20227033763A KR 20220148869 A KR20220148869 A KR 20220148869A
Authority
KR
South Korea
Prior art keywords
seq
xaa
amino acid
independently
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227033763A
Other languages
English (en)
Korean (ko)
Inventor
로렌 디 왈렌스키
그레고리 에이치 버드
Original Assignee
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다나-파버 캔서 인스티튜트 인크. filed Critical 다나-파버 캔서 인스티튜트 인크.
Publication of KR20220148869A publication Critical patent/KR20220148869A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227033763A 2020-03-04 2021-03-04 구조적으로 안정화된 항바이러스성 SARS-CoV-2 펩타이드 및 그의 용도 Pending KR20220148869A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985100P 2020-03-04 2020-03-04
US62/985,100 2020-03-04
PCT/US2021/020940 WO2021178714A2 (en) 2020-03-04 2021-03-04 ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF

Publications (1)

Publication Number Publication Date
KR20220148869A true KR20220148869A (ko) 2022-11-07

Family

ID=75223491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033763A Pending KR20220148869A (ko) 2020-03-04 2021-03-04 구조적으로 안정화된 항바이러스성 SARS-CoV-2 펩타이드 및 그의 용도

Country Status (8)

Country Link
US (1) US20240124529A1 (enExample)
EP (1) EP4114431A2 (enExample)
JP (1) JP7894318B2 (enExample)
KR (1) KR20220148869A (enExample)
CN (1) CN115811984A (enExample)
AU (1) AU2021230544A1 (enExample)
CA (1) CA3173973A1 (enExample)
WO (1) WO2021178714A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524911A (ja) * 2020-04-24 2023-06-13 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としての脂質－ペプチド融合物阻害剤
CN113817026B (zh) * 2021-09-16 2023-06-30 中国人民解放军海军军医大学 靶向刺突蛋白hr1的订书肽、制备方法及抗新型冠状病毒应用
CN113773370B (zh) * 2021-10-15 2022-07-22 哈尔滨吉象隆生物技术有限公司 一种抗病毒的多肽及其应用
US20260232759A1 (en) * 2021-10-22 2026-08-13 Wisconsin Alumni Research Foundation Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease
CN114437196A (zh) * 2022-02-16 2022-05-06 复旦大学 一种抑制SARS-CoV-2感染的蛋白及其用途
EP4611789A1 (en) * 2022-11-06 2025-09-10 Leyden Laboratories B.V. Sars-cov-2 binding polypeptide
WO2024186980A2 (en) * 2023-03-08 2024-09-12 Dana-Farber Cancer Institute, Inc. Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
WO2025235945A1 (en) * 2024-05-10 2025-11-13 Red Queen Therapeutics, Inc. Methods of treating viral infections using a fusion inhibitor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US20080027006A1 (en) 2004-02-12 2008-01-31 The Regents Of The University Of Colorado Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
US7491489B2 (en) * 2004-11-22 2009-02-17 The University Of Hong Knog Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
WO2007005249A2 (en) * 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
JP2011522796A (ja) * 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
WO2010060112A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP2376100B1 (en) * 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
CN102939101A (zh) * 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
GB2473525B (en) 2010-07-19 2011-07-27 Alexander P Fisher System and method for growing plants
WO2014055564A1 (en) * 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3782638A1 (en) * 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CN107022008B (zh) 2016-01-30 2021-04-23 山西锦波生物医药股份有限公司 广谱地抑制人类冠状病毒感染的多肽及其应用
US20190048038A1 (en) 2016-02-23 2019-02-14 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
US10004200B1 (en) * 2017-05-08 2018-06-26 Pioneer Hi-Bred International, Inc. Soybean variety P000A87R
CN108395471B (zh) * 2018-01-15 2020-03-13 中国人民解放军军事科学院军事医学研究院 抑制MERS-CoV感染的多肽

Also Published As

Publication number Publication date
AU2021230544A1 (en) 2022-09-01
CA3173973A1 (en) 2021-09-10
CN115811984A (zh) 2023-03-17
WO2021178714A2 (en) 2021-09-10
US20240124529A1 (en) 2024-04-18
JP2023517293A (ja) 2023-04-25
WO2021178714A3 (en) 2022-02-17
JP7894318B2 (ja) 2026-07-23
EP4114431A2 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US20240124529A1 (en) ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
CA2862391C (en) Stabilized antiviral fusion helices
US20250084128A1 (en) ANTIVIRAL STRUCTURALLY-STAPLED SARS-CoV-2 PEPTIDE-CHOLESTEROL CONJUGATES AND USES THEREOF
US20240131124A1 (en) Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
KR20230170918A (ko) 펩티드 및 펩티드를 포함하는 조성물
WO2019136824A1 (zh) 抑制MERS-CoV感染的多肽
JP7854211B2 (ja) ヘマグルチニン結合ペプチド
US20240052330A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof
WO2024186980A2 (en) Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
US20250288658A1 (en) Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
US20240002450A1 (en) Antiviral structurally-stabilized ebolavirus peptides and uses thereof
CN117858889A (zh) 肽及包含肽的组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000